Cannabis Law Report

JUNE 10, 2021

CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”. Media Contacts: Monica M. Jaramillo, mjaramillo@labeltheagency.com Kathryn Brown CMW Media, kathryn@cmwmedia.com. About CURE Pharmaceutical Holding Corp.

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The public hearing attracted over 100 speakers and 2000 participants. The FDA has historically been passive in its oversight of CBD products.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Cannabis Law Report

JULY 24, 2021

This expansive patent would allow Mydecine to scale its coverage in drug development research in lieu of promising discoveries and FDA-approval progress for novel therapeutics, including granting Breakthrough Therapy Designation to MDMA for the treatment of PTSD in recent years. For more information, please contact: Media Contacts.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. 2021.06.005.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 27, 2020

Those lessons include what’s been happening in states that have legalized marijuana – including various problems with everything from taxation and regulation to road safety – as well as input from state lawmakers and border states with New York that are eyeing marijuana legalization as well. Read the full report at [link].

Media 45

Media Programs Safety Treatment 45

The Blunt Truth

MAY 26, 2020

In his statement, Commissioner Hahn noted that the FDA was working on: 1) continuing to educate the public on the risks of CBD; 2) seeking reliable data on the safety and benefits of CBD, including opening the public docket on the matter; and 3) monitoring the marketplace for the sale and marketing of unapproved drugs.

CBD 103

CBD Hemp Programs Food 103

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Leadership hires in clinical science, regulatory affairs, clinical safety, quality and manufacturing, in preparation for phase III, new compounds and additional indications.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA is aware of media reports of delta-8 THC products getting consumers “high.” brownies, gummies).

THC 105

THC Pets Events Hemp 105

SpeedWeed

FEBRUARY 18, 2021

It also found that decades of cannabis prohibition have failed to achieve public health and safety goals and have led to unjust arrests and convictions, particularly in communities of color. The post Vicaa Launches Website Offering Range of High-Quality Growing Media for Medical Cannabis appeared first on SpeedWeed.

Media 40

Media Decriminalization Safety Programs 40

Veriheal

MARCH 1, 2022

The campaign manager of the ‘Yes on 109’ campaign that helped see the measure passed, Sam Chapman, told media sources, “There’s a huge breadth of expertise on this board from harm reduction experts to folks that have experience working with different populations that stand to benefit from having access to psilocybin therapy.

Therapy 98

Therapy Programs Microdosing Medicine 98

Veriheal

MAY 17, 2021

Theodore happens to also be an addiction expert who refuses to provide treatment to patients that choose to consume cannabis as he believes it interferes with the treatment of other addictions. She ends the column by stating “ I urge our legislators to abandon this legislation for the sake of our citizen’s health and safety.”.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

CannaMD

MARCH 19, 2020

As Florida’s leading medical cannabis physicians , CannaMD is committed to working closely with licensed dispensaries to ensure medical cannabis patients stay safe while continuing uninterrupted treatment during the coronavirus (COVID-19) crisis. As always, we remain committed to your safety, and look forward to continuing to serve you.

Policy 98

Policy Dispensary Patients Safety 98

Alchimia

MARCH 16, 2016

Although a balanced nutrition – and regular brain stimulation – can have protective and preventive effects , we still don’t have any effective treatment for Alzheimer’s disease once it is active. Cannabinoids for treatment of Alzheimer?s See studies #2, 3, 4, 6, 9, 10). They actually protect our neurons!

Cannabinoids 76

Cannabinoids Research and Development Treatment Patients 76

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

OCTOBER 4, 2021

As a result, the TGA had not evaluated these products for quality, safety or efficacy and the manufacturer had not obtained relevant approvals. The TGA alleges that the individual also made a prohibited representation , on a related social media platform, in relation to the use of CBD oil for the treatment of cancer.

Law 52

Law Treatment Medicine CBD 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For media inquiries please contact: Michael Sharp. Orphan Drug Designation?

DEA 51

DEA Clinical Trials THC Research and Development 51

Cannabis Law Report

OCTOBER 6, 2021

Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market.”. About DELIC Corp. The Canadian Securities Exchange ?has for the adequacy or accuracy of this release.?.

Research and Development 52

Research and Development Extraction Treatment Safety 52

CannaMD

JULY 13, 2020

Due to the federal restrictions on cannabis use, research about marijuana’s safety and effects has been limited. Measuring marijuana intoxication has garnered increased media attention as police seek ways to monitor marijuana-impaired drivers in legalized cannabis states. These include: Verbal recall (memory). Selective attention.

THC 96

THC Concentrates Cannabinoids Marijuana 96

Cannabis Law Report

MAY 30, 2021

Lansing City Pulse reports… A graphic circulating on social media encourages customers to boycott several cannabis brands affiliated with the Michigan Cannabis Manufacturers Association. Their products also don’t have to be tested at a safety compliance laboratory. Its source is unknown. Posted Friday, May 28, 2021 2:15 pm.

Patients 105

Patients Retail Cannabis Legislation 105

Cannabis Law Report

APRIL 13, 2022

Securing a Dealer’s License to accompany its existing research exemptions would cement Delic Labs’ position as the leader in psychedelic safety testing. The Company aims to establish consistent quality control standards as more patients and clinicians incorporate psychedelic compounds into treatment plans.

Research and Development 52

Research and Development Treatment Extraction Medicine 52

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Delta-8 is known to be successful in many cancer treatments.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

MARCH 6, 2020

Europe is on the forefront of pharmaceutical development in the growing market for cannabinoid receptor target therapeutics which should bring further attention to our efforts in moving KLS-13019 forward for the treatment of neuropathic pain and other CNS disorders associated with neuroinflammation,” said Dean Petkanas , CEO of Kannalife.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Cannabis Law Report

DECEMBER 9, 2021

The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. At 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JANUARY 13, 2020

Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. Media Enquiries: Sam Brown Inc. media enquiries.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

MMJ Recs

OCTOBER 13, 2023

For patients seeking access to this valuable form of treatment, it’s essential to understand the complex web of regulations, legal requirements, and rights surrounding medical marijuana in the Golden State. California has long been a pioneer in the field of medical marijuana, and its MMJ laws have continued to evolve over the years.

Patients 52

Patients Law Cultivation Dispensary 52

Veriheal

AUGUST 12, 2021

The authors added that in spite of the growing availability and diversity of alternative cannabinoid products like artisanal CBD—as opposed to pharmaceutical CBD—existing studies assessing their efficacy and/or safety are extremely rare. The majority of patients (74%) were Caucasian and more than half (55%) identified as female.

Epilepsy 81

Epilepsy Pharmaceutical Patients Sleep 81

MMJ Recs

OCTOBER 5, 2023

With a growing number of MMJ dispensaries, a comprehensive set of laws, and a streamlined process for obtaining a medical marijuana card, the state has become a hub for patients seeking alternative treatments. These laws are designed to protect patients, provide access to treatment, and prevent abuse.

Dispensary 52

Dispensary Patients Treatment Conditions 52

Cannabis Law Report

MAY 26, 2022

So we need to discuss openly and critically how we can remain balanced and ensure the potential of psychedelics can be optimised without compromising safety.”. And how do we make sure treatments are safe, accessible, and inclusive? Learn more about ICPR 2022 by connecting on social media using the #ICPR2022 hashtag.

Research and Development 52

Research and Development Therapy Policy Media 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. This article analyses media representations of medicinal cannabis in Australian medical publications. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., For Alzheimer’s patients, CBD is one treatment option that is slowing the progression of that disease.”.

CBD 40

CBD Research and Development Safety Therapy 40

Cannabis Law Report

JANUARY 24, 2022

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Edwin (Ed) Tucker, M.D., Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS Goldfinch Bio: Investors: Hannah Deresiewicz.

Clinical Trials 40

Clinical Trials Research and Development Data Medicine 40

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

MMJ Recs

MAY 29, 2024

For many patients, traditional treatment options may fall short of providing relief from debilitating symptoms. Patients must have a certification from a registered physician confirming their diagnosis and recommending medical marijuana as a treatment option. Image by Iñaki del Olmo on Unsplash. You can find an approved physician here.

Marijuana 52

Marijuana Programs Patients Conditions 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS Poster Number: INFO37.

Clinical Trials 40

Clinical Trials Research and Development Data Patients 40